VTVT (vTv Therapeutics Inc) Earnings growth in current year

VTVT (vTv Therapeutics Inc.) - company brandmark

vTv Therapeutics Inc. (VTVT) generates revenue through the implementation of metabolic therapy by developing the drug TTP399. The company's environmental focus is based on energy efficiency and the safe disposal of chemicals. Innovations rely on TTP inhibitors to combat diabetes. The EPS trajectory compared to last year reflects market expectations, where the value of 47.10 characterizes the current level of stock profitability.

VTVT: vtvtherapeutics.com Earnings per share growth in current year 07/04/2022 - 11/18/2026

Financial and market metric breakdowns for vTv Therapeutics Inc. (VTVT)

- share price and expert price forecast:
Basic company analysis:VTVT - vtvtherapeutics.com
Finished products of vTv Therapeutics Inc

The use of AI in molecular screening for diabetes drugs optimizes costs for vTv Therapeutics Inc. (VTVT). The dynamics of EPS compared to the same period last year reflect the percentage change in net income per share. The growth of this metric confirms the efficiency of automated drug synthesis. The stable trajectory of the line minimizes capitalization volatility risks. This positive trend indicates the high investment attractiveness of the business.

Main competitors

ASND: Net earnings per one share growth for the current year|MDGL (Madrigal Corp) - Earnings growth in current year|Earnings growth in current year Corcept Therapeutics|Earnings growth in current year RYTM|Earnings per share growth in current year AKRO (Akero Therapeutics, Inc.)|Earnings per share growth in current year metsera.com MTSR|MoonLake Corp (MLTX) - Earnings per share growth rate in current year|CRNX - Earnings per share growth in current year|NAMS: Earnings per share growth in current year|SLNO: Earnings growth in current year|FOLD - Expected net earnings per share growth this year|Earnings per share growth in current year 89bio Pharma|Agios Corp (AGIO) - Expected net earnings per share growth this year|Earnings per share growth in current year structuretx.com (GPCR)|Net earnings per share growth this year mimedx.com MDXG|Earnings per share growth in current year Rezolute RZLT|Lexicon Pharmaceuticals, Inc. - Earnings per share growth in current year|MBX: Net earnings per share growth this year|Altimmune Corp - Net earnings per one share growth for the current year|Aardvark Therapeutics Inc (AARD) - Earnings per share growth in current year|Net earnings per share change in current year Sagimet Biosciences SGMT|BIOA (bioagelabs.com) - Earnings growth in current year|Net earnings per share growth this year Biomea Fusion (BMEA)|Earnings growth in current year QNCX|Net earnings per one share growth for the current year GUTS|Agape ATP Corporation - Net earnings per share growth this year|Earnings per share increase in current year PLUR|Synlogic Inc. - Earnings growth in current year|LPCN (Lipocine) - Earnings per share growth this year|MTNB (Matinas BioPharma Holdings Inc.) - Net earnings per share growth this year|SPRB (Spruce Biosciences, Inc.) - Earnings per share growth in current year|GLTO (galecto.com) - Earnings growth in current year|Net earnings per share growth this year carmellrx.com (CTCX)|Earnings per share growth in current year Lumos Pharma (LUMO)|ONVO (Organovo Holdings) - Earnings per share increase in current year|radiuspharm.com - Net earnings per share growth this year